You are here

h1n1Flu -pandemic- Interim Guidance on Pneumococcal polysaccharideVaccines

Interim guidance for use of 23-valent pneumococcal polysaccharide vaccine during novel influenza A (H1N1) outbreak June 9, 2009 Table. U.S. ACIP recommendations for use of pneumococcal polysaccacharide vaccine.

U.S. ACIP recommendations for use of pneumococcal polysaccacharide vaccine.

Pneumococcal polysaccharide vaccine (PPSV23)

Universal vaccination

All adults 65 years of age and older

Medical Indications

Persons 2 through 64 years of age who have one or more of the following long-term health problems:

* chronic cardiovascular disease (congestive heart failure and cardiomyopathies)
* chronic pulmonary disease including chronic obstructive pulmonary disease and emphysema
* diabetes mellitus
* alcoholism
* chronic liver disease, including cirrhosis
* cerebrospinal fluid leaks
* functional or anatomic asplenia including sickle cell disease and splenectomy
* immunocompromising conditions including HIV infection, leukemia, lymphoma, Hodgkin’s disease, multiple myeloma, generalized malignancy, chronic renal failure, nephrotic syndrome; those receiving immunosuppressive chemotherapy (including corticosteroids); and those who have received an organ or bone marrow transplant

Adults 19 through 64 years of age who:

* smoke cigarettes
* have asthma

... read full recommendations and more